Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Plexxikon
July 07, 2014
No respite for private biotech takeovers
July 02, 2014
If you thought Aragon’s exit was impressive, check out Seragon
May 21, 2014
Asco preview – Failed brain cancer project gets a second shot
July 16, 2013
Early-stage asset risk no deterent to partnering deals
February 07, 2013
M&A activity cools in 2012 as break-ups loom
November 24, 2011
History not on Gilead's side in high stakes gamble on Pharmasset
August 23, 2011
Encouraging 2011 M&A trends seen but big pharma inactivity concerning
March 03, 2011
Event - BMS readies for two big ipi events
March 01, 2011
Daiichi pays handsome price for Plexxikon
September 10, 2010
Therapeutic focus - Melanoma awaiting breakthrough but data approaching
February 25, 2010
Resurgence of conventional and untrendy therapy area product deals in 2009
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
March 22, 2021
AACR 2021 preview – the early themes emerge
March 24, 2021
Big pharma’s key catalysts in the second quarter
March 03, 2021
A busy year ahead for Parkinson’s disease
March 23, 2021
Frequency refuses to hear the death knell
February 18, 2021
The reckoning begins for biotech-focused Spacs
